GSK plc (GSK.L)
- Previous Close
1,583.50 - Open
1,579.50 - Bid --
- Ask --
- Day's Range
1,575.00 - 1,589.00 - 52 Week Range
1,302.60 - 1,725.81 - Volume
951,575 - Avg. Volume
9,048,789 - Market Cap (intraday)
64.693B - Beta (5Y Monthly) 0.27
- PE Ratio (TTM)
13.19 - EPS (TTM)
1.20 - Earnings Date May 1, 2024
- Forward Dividend & Yield 0.64 (4.04%)
- Ex-Dividend Date Feb 22, 2024
- 1y Target Est
--
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
www.gsk.com70,212
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: GSK.L
Performance Overview: GSK.L
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GSK.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GSK.L
Valuation Measures
Market Cap
64.70B
Enterprise Value
77.73B
Trailing P/E
13.21
Forward P/E
10.08
PEG Ratio (5yr expected)
1.06
Price/Sales (ttm)
2.15
Price/Book (mrq)
4.85
Enterprise Value/Revenue
2.56
Enterprise Value/EBITDA
8.56
Financial Highlights
Profitability and Income Statement
Profit Margin
16.25%
Return on Assets (ttm)
8.81%
Return on Equity (ttm)
46.38%
Revenue (ttm)
30.33B
Net Income Avi to Common (ttm)
4.93B
Diluted EPS (ttm)
1.20
Balance Sheet and Cash Flow
Total Cash (mrq)
5.69B
Total Debt/Equity (mrq)
140.82%
Levered Free Cash Flow (ttm)
3.56B